TABLE OF CONTENTS 1. INTRODUCTION 1.1. OBJECTIVES OF THE STUDY 1.2. MARKET DEFINITION 1.3. OVERVIEW OF NORTH AMERICA CANCER DIAGNOSTICS MARKET 1.4. CURRENCY AND PRICING 1.5. LIMITATION 1.6. MARKETS COVERED 2. MARKET SEGMENTATION 2.1. MARKETS COVERED 2.2. GEOGRAPHIC SCOPE 2.3. YEARS CONSIDERED FOR THE STUDY 2.4. CURRENCY AND PRICING 2.5. RESEARCH METHODOLOGY 2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.7. SECONDARY SOURCES 2.8. ASSUMPTIONS 3. MARKET OVERVIEW 3.1. DRIVERS 3.1.1. GROWTH OF AGING POPULATION AND RISING PREVALENCE OF CANCER 3.1.2. GOVERNMENT INITIATIVES FOR FUNDING AND AWARENESS ABOUT CANCER 3.1.3. KEY PLAYERS FOCUSING ON STRATEGIC DECISIONS TO GAIN MARKET SHARE 3.1.4. INCREASING PREVELANCE OF CANCER   3.2. RESTRAINTS 3.2.1. STRINGENT REULATIONS IMPOSED BY INTERNATIONAL AND LOCAL AUTHORITIES 3.2.2. SHORTAGE OF SKILLED AND TRAINED PROFESSIONALS 3.3. OPPORTUNITIES 3.3.1. NANOTECHNOLOGY: FORTHCOMING REVOLUTION IN CANCER DIAGNOSIS 3.3.2. ARTIFICIAL INTELLIGENCE AND THE IMMINENT HEALTH REVOLUTION 3.3.3. GROWING MEDICAL TOURISM IN ASIA 3.4. CHALLENGES 3.4.1. INCREASING RIVALRY AMONG THE COMPETITORS 3.4.2. POOR ACCESS TO CANCER DETECTION AND HIGH TREATMENT COCTS IN LOWER INCOME COUNTRIES 4. PREMIUM INSIGHTS 5. EXECUTIVE SUMMARY 6. NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 6.1. OVERVIEW 6.2. PLATFORM BASED 6.2.1. POLYMERASE CHAIN REACTION(PCR) 6.2.2. IN SITU HYBRIDIZATION (ISH) 6.2.3. IMMUNOHISTOCHEMISTRY(IHC) 6.2.4. NEXT GENERATION SEQUENCING (NGS) 6.2.5. DNA MICROARRAYS 6.2.6. FLOW CYTOMETRY 6.3. INSTRUMENT BASED 6.3.1. IMAGING 6.3.1.1. MAGENTIC RESONANCE IMAGING (MRI) 6.3.1.2. CT(COMPUTED TOMOGRAPHY) 6.3.1.3. POSITRON EMISSION TOMOGRAPHY- COMPUTED TOMOGRAPHY (PET-CT) 6.3.1.4. MAMMOGRAPHY 6.3.1.5. ULTRASOUND 6.3.2. BIOPSY 7. NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION 7.1. OVERVIEW 7.2. LUNG CANCER 7.3. BREAST CANCER 7.4. COLORECTAL CANCER 7.5. MELANOMA 7.6. OTHERS 8. NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY 8.1. OVERVIEW 8.2. NORTH AMERICA CANCER DIAGNOSTICS MARKET 8.2.1. U.S.CANCER DIAGNOSTICS MARKET 8.2.2. CANADA CANCER DIAGNOSTICS MARKET 8.2.3. MEXICO CANCER DIAGNOSTICS MARKET 9. NORTH AMERICA CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 9.1. COMPANY SHARE ANALYSIS: NORTH AMERICA CANCER DIAGNOSTICS IMAGING MARKET 9.2. COMPANY SHARE ANALYSIS: NORTH AMERICA CANCER DIAGNOSTICS PLATFORM BASED MARKET 10. COMPANY PROFILES 10.1. C. R. BARD, INC. 10.1.1. COMPANY OVERVIEW 10.1.2. REVENUE ANALYSIS 10.1.3. PRODUCT PORTFOLIO 10.1.4. RECENT DEVELOPMENTS 10.2. ILLUMINA, INC. 10.2.1. COMPANY OVERVIEW 10.2.2. REVENUE ANALYSIS 10.2.3. RECENT DEVELOPMENTS 10.2.4. PRODUCT PORTFOLIO 10.3. QIAGEN 10.3.1. COMPANY OVERVIEW 10.3.2. REVENUE ANALYSIS 10.3.3. RECENT DEVELOPMENTS 10.3.4. PRODUCT PORTFOLIO 10.4. ABBOTT 10.4.1. COMPANY OVERVIEW 10.4.2. REVENUE ANALYSIS 10.4.3. RECENT DEVELOPMENTS 10.4.4. PRODUCT PORTFOLIO 10.5. SIEMENS HEALTHCARE GMBH 10.5.1. COMPANY OVERVIEW 10.5.2. REVENUE ANALYSIS 10.5.3. RECENT DEVELOPMENTS 10.5.4. PRODUCT PORTFOLIO 10.6. AGILENT TECHNOLOGIES 10.6.1. COMPANY OVERVIEW 10.6.2. REVENUE ANALYSIS 10.6.3. PRODUCT PORTFOLIO 10.6.4. RECENT DEVELOPMENTS 10.7. THERMO FISHER SCIENTIFIC INC. 10.7.1. COMPANY OVERVIEW 10.7.2. REVENUE ANALYSIS 10.7.3. PRODUCT PORTFOLIO 10.7.4. RECENT DEVELOPMENTS 10.8. BECTON, DICKINSON AND COMPANY 10.8.1. COMPANY OVERVIEW 10.8.2. REVENUE ANALYSIS 10.8.3. PRODUCT PORTFOLIO 10.8.4. RECENT DEVELOPMENTS 10.9. GE HEALTHCARE 10.9.1. COMPANY OVERVIEW 10.9.2. REVENUE ANALYSIS 10.9.3. PRODUCT PORTFOLIO 10.9.4. RECENT DEVELOPMENTS 10.10. F. HOFFMANN-LA ROCHE LTD 10.10.1. COMPANY OVERVIEW 10.10.2. REVENUE ANALYSIS 10.10.3. PRODUCT PORTFOLIO 10.10.4. RECENT DEVELOPMENTS 10.11. HOLOGIC INC. 10.11.1. COMPANY OVERVIEW 10.11.2. REVENUE ANALYSIS 10.11.3. RECENT DEVELOPMENTS 10.11.4. PRODUCT PORTFOLIO 10.12. KONINKLIJHE PHILIPS N.V. 10.12.1. COMPANY OVERVIEW 10.12.2. REVENUE ANALYSIS 10.12.3. PRODUCT PORTFOLIO 10.12.4. RECENT DEVELOPMENTS 11. RELATED REPORTS

TABLE LIST TABLE 1 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION) TABLE 2 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 3 NORTH AMERICA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 4 NORTH AMERICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 5 NORTH AMERICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 6 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 7 U.S.CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 8 U.S. PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 9 U.S. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 10 U.S. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 11 U.S. CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 12 CANADA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 13 CANADA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 14 CANADA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 15 CANADA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 16 CANADA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 17 MEXICO CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 18 MEXICO PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 19 MEXICO INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 20 MEXICO INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 21 MEXICO CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) FIGURES LIST FIGURE 1 NORTH AMERICA CANCER DIAGNOSTICS MARKET SNAPSHOT (2017) FIGURE 2 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY (2016) FIGURE 3 NORTH AMERICA CANCER DIAGNOSTICS MARKET : BY COUNTRY (2017) FIGURE 4 NORTH AMERICA CANCER DIAGNOSTICS MARKET BY COUNTRY (2016 & 2024) FIGURE 5 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY (2017 & 2024)

• GE Healthcare • Siemens Healthcare GmbH • Hologic, Inc, • Becton, Dickinson & Company. • Thermo Fisher Scientific, Inc. • Illumina, Inc. • Roche Diagnostics, • Abbott Laboratories, Inc. • QIAGEN.